Minnesota Natural Medicine General Practice Medicare: Not Enrolled in Medicare Practice Location: 3485 Willow Lake Blvd, #100, Vadnais Heights, MN 55110 Phone: 651-484-5567 |
Northeast Pediatric Clinic Clinic/Center - Primary Care Medicare: Not Enrolled in Medicare Practice Location: 4520 Centerville Rd, Vadnais Heights, MN 55127 Phone: 651-426-1141 |
Entira Family Clinics-vadnais Heights Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 3550 Labore Rd Ste 7, Vadnais Heights, MN 55110 Phone: 651-788-4444 Fax: 651-766-9451 |
Healtheast Vadnais Heights Clinic Clinic/Center Medicare: Medicare Enrolled Practice Location: 1055 Centerville Cir, Vadnais Heights, MN 55127 Phone: 651-326-5900 Fax: 651-426-8935 |
Northeast Pediatric Clinic P.a. Clinic/Center - Primary Care Medicare: Not Enrolled in Medicare Practice Location: 4520 Centerville Rd, Vadnais Heights, MN 55127 Phone: 651-426-1141 Fax: 651-426-1705 |
Allina Health Vadnais Heights Clinic Family Medicine Medicare: Medicare Enrolled Practice Location: 1155 County Road E E, Suite 100, Vadnais Heights, MN 55110 Phone: 651-241-9200 Fax: 651-241-9203 |
News Archive
The first study looking at the effect of chlorhexidine mouthwash on the entire oral microbiome has found its use significantly increases the abundance of lactate-producing bacteria that lower saliva pH, and may increase the risk of tooth damage.
New Canadian research suggests that your canine friend may be able to predict epileptic seizures in children a few hours in advance.
The U.S. Food and Drug Administration has announced it will require the manufacturers of antiepileptic drugs to add to these products' prescribing information, or labeling, a warning that their use increases risk of suicidal thoughts and behaviors (suicidality). The action includes all antiepileptic drugs including those used to treat psychiatric disorders, migraine headaches and other conditions, as well as epilepsy.
SuperSonic Imagine, the innovative producer of ultrasound equipment, announced today that it has signed an exclusive distribution agreement with Hologic, Inc. to develop the breast ultrasound market in the United States.
The biopharmaceutical company Antisense Pharma announced today that the US-American Food and Drug Administration (FDA) has issued an Investigational New Drug (IND)-authorisation for clinical studies with trabedersen for patients with high-grade glioma. This authorisation entitles the company to include US-American clinics both in the phase III study SAPPHIRE and in further studies.
› Verified 2 days ago